Parallax Volatility Advisers, L.P. Cassava Sciences Inc Transaction History

Parallax Volatility Advisers, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$21.59 - $27.88 $180,924 - $233,634	8,380 Added 7618.18%	8,490 $208,000
Q1 2023 May 15, 2023	SELL	$23.46 - $36.44 $601,702 - $934,613	-25,648 Reduced 99.57%	110 $2,000
Q4 2022 Feb 14, 2023	SELL	$27.82 - $44.16 $74,752 - $118,657	-2,687 Reduced 9.45%	25,758 $760,000
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $464,506 - $1.45 Million	28,445 New	28,445 $1.19 Million

190

16.4M

3.49M

8.08M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $102M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.